{"id":"W4379333019","doi":"10.1200/jco.2023.41.16_suppl.4568","title":"Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Seagen","keywords":"Medicine; Internal medicine; Clinical endpoint; Cohort; Pembrolizumab; Oncology; Cancer; Cisplatin; Urology; Progression-free survival; Chemotherapy; Randomized controlled trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001060485,0.0005695389,0.0009775432,0.0003350545,0.0003000234,0.0006818307,0.0004544866,0.0006124474,0.002251756],"category_scores_gemma":[0.0008624179,0.0002713437,0.001220954,0.0002883446,0.0004883413,0.000764324,0.0003609328,0.001435129,0.0004859437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006988365,"about_ca_system_score_gemma":0.0008198106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007457,"about_ca_topic_score_gemma":0.00309226,"domain_scores_codex":[0.9996607,0.0001425837,0.00002150866,0.00005897901,0.00002873111,0.0000875646],"domain_scores_gemma":[0.9994177,0.0001102592,0.0001556986,0.00007876692,0.00002319481,0.0002143645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8407778,0.02978012,0.02356601,0.0003591287,0.001361423,0.0001985854,0.0001927397,0.001830088,0.01560756,0.0001425736,0.002104696,0.0840793],"study_design_scores_gemma":[0.2380034,0.6624566,0.083827,0.00008462238,0.00161566,0.0004104749,0.0001822015,0.001928797,0.005650857,0.000324993,0.005470345,0.00004503829],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997319,0.0005450447,0.0001364842,0.00008993936,0.00002733167,0.00042605,0.0008124903,0.00001527294,0.0006283533],"genre_scores_gemma":[0.9966142,0.0004334386,0.0003580606,0.0001655315,0.00003771589,0.0004084455,0.00122126,0.00000669696,0.0007547752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002251756,"threshold_uncertainty_score":0.007532835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1017050838108016,"score_gpt":0.4359688664735234,"score_spread":0.3342637826627218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}